SOCMA Lends Support for Measures Addressing Nontariff Barriers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

SOCMA Lends Support for Measures Addressing Nontariff Barriers


ePT--the Electronic Newsletter of Pharmaceutical Technology

The Society of Chemical Manufacturers and Affiliates (SOCMA) issued a statement to support a recently introduced bill intended to help the federal government deal with market-access barriers more effectively. The bill, HR 3112, the Trade Law Enforcement Act, was introduced by Rep. Michael Turner (R-OH) on Oct. 6, 2011. The bill would formalize the process by which the Office of the United States Trade Representative (USTR) acts on market-access barriers that are deemed unlawful under US trade agreements.

“This bill elevates a process already in place for companies to report the unfair practices they are experiencing for investigation,” said SOCMA in a Nov. 3, 2011, press statement. “Formalizing the process allows companies to understand the resources that exist within the government, which often they do not know exist. In a time when businesses are looking more at new opportunities to export abroad to growing markets, having a resource such as this to ensure that companies can take full advantage of opportunities and agreements we have in place is extremely important.”

Under current law, the USTR has the ability to respond to various trade practices deemed unfair, including market-access problems caused by nontariff barriers. SOCMA says that while US manufacturers can petition the USTR to take action, they seldom do, partly because of the cost of compiling an adequate petition and the uncertainty of getting timely relief.

SOCMA is urging other members of Congress to show their support for the legislation. SOCMA is the US-based trade association representing custom and batch manufacturers, including producers of fine chemicals, pharmaceutical intermediates, and APIs.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here